Factor Model (net -2.6)
Factor Model
net -2.6 5.4 / 10Sionna draws $45M insider buys, Wedbush starts coverage
Watch: Phase 2a PreciSION study data expected summer 2026 will be critical to validate drug efficacy and drive next valuation step.
Insiders and firms like RA Capital and Orbimed purchased $45M shares around $18-$25, signaling strong conviction. Wedbush initiated coverage with an Outperform rating and $53 target, boosting confidence. JonesResearch raised its target to $63 after Phase 2a PreciSION enrollment completion; data expected summer 2026. Despite insider selling pressure, multiple buyers suggest bullish institutional view amid a 12% price dip from 52-week high.
The strong insider and institutional buying combined with analyst upgrades signals growing confidence in Sionna's biotech pipeline and upcoming clinical readouts, likely supporting a re-rate in valuation and share price.
Evidence
7 older signals
Fundamentals & Data ▾
Recent transactions
Keep reading the market
Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.